JP2025506473A - ヘテロ環glp-1アゴニスト - Google Patents

ヘテロ環glp-1アゴニスト Download PDF

Info

Publication number
JP2025506473A
JP2025506473A JP2024547305A JP2024547305A JP2025506473A JP 2025506473 A JP2025506473 A JP 2025506473A JP 2024547305 A JP2024547305 A JP 2024547305A JP 2024547305 A JP2024547305 A JP 2024547305A JP 2025506473 A JP2025506473 A JP 2025506473A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
group
optionally substituted
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506473A5 (https=
Inventor
モン,チンホア
シン,ウェイチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gasherbrum Bio Inc
Original Assignee
Gasherbrum Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gasherbrum Bio Inc filed Critical Gasherbrum Bio Inc
Publication of JP2025506473A publication Critical patent/JP2025506473A/ja
Publication of JP2025506473A5 publication Critical patent/JP2025506473A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024547305A 2022-02-09 2023-02-08 ヘテロ環glp-1アゴニスト Pending JP2025506473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/075604 2022-02-09
CN2022075604 2022-02-09
PCT/CN2023/074936 WO2023151574A1 (en) 2022-02-09 2023-02-08 Heterocyclic glp-1 agonists

Publications (2)

Publication Number Publication Date
JP2025506473A true JP2025506473A (ja) 2025-03-11
JP2025506473A5 JP2025506473A5 (https=) 2026-02-17

Family

ID=87563618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547305A Pending JP2025506473A (ja) 2022-02-09 2023-02-08 ヘテロ環glp-1アゴニスト

Country Status (5)

Country Link
US (1) US20250177362A1 (https=)
EP (1) EP4476216A4 (https=)
JP (1) JP2025506473A (https=)
CN (1) CN119343343A (https=)
WO (1) WO2023151574A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環glp—1促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025222008A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Glucagon receptor agonists and their use as therapies
WO2025222000A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Substituted 1,1'-biphenyl compounds as glucagon receptor agonists
WO2026078617A1 (en) * 2024-10-11 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
KR102314286B1 (ko) * 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP2023537501A (ja) * 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
JP2025506474A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト

Also Published As

Publication number Publication date
US20250177362A1 (en) 2025-06-05
WO2023151574A1 (en) 2023-08-17
EP4476216A4 (en) 2025-12-03
CN119343343A (zh) 2025-01-21
EP4476216A1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US12528781B2 (en) Heterocyclic GLP-1 agonists
US11926643B2 (en) Heterocyclic GLP-1 agonists
JP7821785B2 (ja) ヘテロ環glp-1アゴニスト
JP2025506473A (ja) ヘテロ環glp-1アゴニスト
US20240366639A1 (en) Heterocyclic glp-1 agonists
JP2025509281A (ja) ヘテロ環式glp-1アゴニスト
WO2021160127A1 (en) Heterocyclic glp-1 agonists
JP2023524493A (ja) ヘテロ環glp-1アゴニスト
JP2023546054A (ja) ヘテロ環glp-1アゴニスト
JP2023540609A (ja) ヘテロ環glp-1アゴニスト
JP2025506474A (ja) ヘテロ環glp-1アゴニスト
WO2023198140A1 (en) Heterocyclic glp-1 agonists
JP2026501285A (ja) ヘテロ環式glp-1アゴニスト
HK40120672A (zh) 杂环glp-1激动剂
HK40119249A (zh) 杂环glp-1激动剂
HK40083559B (en) Heterocyclic glp-1 agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260206